Insomnia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Insomnia Market Outlook

Thelansis’s “Insomnia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Insomnia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Insomnia Overview

Insomnia is the most common clinical condition in which the person experiences difficulty sleeping and is subclassified as short-term, chronic, and other. Sometimes it is described as the presence of polysomnographic evidence of disturbed sleep. Therefore insomnia is considered to exist when there is long sleep latency, frequent nocturnal awakening, prolonged wakefulness throughout the sleep phase, or transient arousals. Insomnia can be a primary sleep disorder, comorbid sleep condition, and other mental or medical disorders. The etiology includes environmental, genetic, behavioral, and physiological factors culminating in hyperarousal. Insomnia is the complex interaction between cognitive arousal, altered circulation, and the homeostatic system. Decreased function of the sleep-walk switch may also contribute to insomnia. During sleep, there is a gradual shift from non-rapid-eye movement (non-REM) sleep to rapid-eye-movement (REM) sleep. The most common symptom was trouble sustaining sleep(61%), followed by early morning awakening(2.2%), difficulties beginning sleep(7.7%), and nonrestorative sleep (7.7%). The American Academy of Sleep Medicine divides rest into five stages: Stage W (wakefulness), Stage N1 (relaxed wakefulness), Stage N2 (light sleep), Stage N3 (deep or slow-wave sleep), and Stage R (REM sleep or dreaming). N1-N3 are non-REM sleep stages with minimal cortical activity, whereas REM sleep has significant cortical activity.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2024–2034)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Insomnia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Comments

Post a Comment